Dr Lal PathLabs Limited has filed its Annual Report for the Financial Year 2025-26 with the National Stock Exchange of India Limited and BSE Limited, pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report was submitted on July 1, 2026, and signed by Vinay Gujral, Company Secretary & Compliance Officer.

Financial Performance: Consolidated and Standalone

The company delivered consistent growth across both consolidated and standalone metrics in FY 2025-26. The following table summarises the key financial results:

Consolidated revenue from operations reached ₹27,629 million in FY 2026, up 12.2% from ₹24,614 million in FY 2025. Reported EBITDA for FY 2026 stood at ₹7,524 million; excluding the one-time charge of ₹301 million related to the implementation of the new Labour Code, EBITDA stood at ₹7,825 million, reflecting growth of 12.5% over FY 2025. EBITDA margins remained steady at 28.3%. On a normalised basis, PAT increased by 17.9% to ₹5,323 million during the year. The company reported cash and cash equivalents of ₹15,262 million in FY 2026, compared to ₹12,295 million in FY 2025, and remains debt-free.

Shareholder Returns: Bonus Issue and Dividend

The Board approved a 1:1 bonus issue, allotting 8,37,75,510 fully paid-up bonus equity shares on December 22, 2025, by capitalising ₹837.75 million from the Securities Premium account. As a result, the paid-up share capital increased from ₹83,59,17,350 to ₹1,67,55,50,200. A total dividend of 280% on equity share capital was declared for FY 2026, comprising the following tranches:

Operational Highlights and Network Expansion

During FY 2025-26, the company added 14 laboratories and over 1,100 collection centres, strengthening its cluster-led expansion strategy. Key operational metrics are summarised below:

Tier 3+ markets contributed 39% of revenue in FY 2026. Over the last four years, the company added 2,625 PSCs and 2,997 pick-up points across India.

Strategic and Innovation Milestones

FY 2025-26 marked several strategic milestones for the company:

• Launch of Sovaaka: An AI-powered precision health screening and preventive wellness platform, inaugurated with the participation of the Chief Minister of Haryana.
• Medllumina: The company's first international medical conference on diagnostics and precision medicine, bringing together over 500 clinicians, researchers and global experts.
• First-in-India Diagnostic Tests: 13 new first-in-India diagnostic tests were introduced during FY 2026, including Amyloid Typing by Laser Capture Microdissection and Mass Spectrometry — the first such offering in South Asia.
• AI in Oncology: The company became the first laboratory in India to integrate a deep learning-based AI module for detecting lymph node metastasis, including micrometastasis.
• R&D: Over 35 internal research projects were initiated, and more than 40 scientific papers were published in national and international journals. R&D expenditure stood at ₹48.55 million.
• Credit Rating Upgrade: The company's credit rating was upgraded from CARE AA; Stable to CARE AA+; Stable.

CSR and Sustainability

The company's CSR arm, Lal PathLabs Foundation, spent ₹102.16 million against a CSR obligation of ₹102.02 million in FY 2025-26. The flagship Phlebotomist Training Program certified 3,100+ candidates and placed 2,500+ candidates during the year, with 62% of certified candidates being women. Since inception in 2018, over 13,000 phlebotomists have been trained and over 10,700+ placed. The Foundation reached over 1,00,000 direct beneficiaries across 42 locations through its public health programmes. On the environmental front, the company's 3.22 MW solar capacity generated 34.60 lakh kWh of green energy in FY 2025-26, resulting in CO2 emissions savings of 2,515 metric tonnes, while its RO wastewater recycling programme recovered approximately 9,125.3 KL of water.

Corporate Governance and Board

The Board comprised nine directors as on March 31, 2026, including two Executive Directors, two Non-Executive Directors and five Non-Executive Independent Directors. The Board met four times during FY 2025-26. Key managerial personnel as on March 31, 2026 included (Hony) Brig Dr Arvind Lal as Executive Chairman, Dr Vandana Lal as Whole-Time Director, Shankha Banerjee as CEO, Ved Prakash Goel as Group CFO & CEO – International Business, and Vinay Gujral as Company Secretary & Compliance Officer. The 32nd Annual General Meeting is scheduled for Saturday, July 25, 2026.

Dr. Lal Path Labs has announced that its board of directors is scheduled to meet on July 24 to consider the company's financial results for the first quarter (Q1).

Board Meeting Details

The upcoming board meeting represents a key corporate event for the diagnostic services company. The following details have been disclosed regarding the scheduled meeting:

Key Takeaways

• Dr. Lal Path Labs has formally scheduled its board meeting for July 24
• The primary agenda of the meeting is to consider the Q1 financial results
• The announcement signals an upcoming disclosure of the company's quarterly performance

Stakeholders and investors are expected to closely monitor the outcome of the board meeting, as the Q1 results will provide insight into the company's financial performance for the quarter. Further details are anticipated to be made available following the conclusion of the meeting on July 24.